NCT07439796 A Study of ORN252 in Healthy Participants
| NCT ID | NCT07439796 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Orna Therapeutics, Inc. |
| Condition | Healthy Volunteers - Male and Female |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-03-16 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 20 participants in total. It began in 2026-03-16 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to assess the safety and tolerability of ORN252 in healthy adult participants.
Eligibility Criteria
Inclusion Criteria: * Male and female participants who are healthy as determined by the Investigator based on review of medical history, physical examination, and laboratory tests * Participant is willing and able to comply with study visits and other protocol requirements * Other protocol specific inclusion criteria may apply Exclusion Criteria: * Clinically significant history or presence of organ dysfunction * Use of any investigational product within 3 months, or 5 half-lives, whichever longer * Other protocol specific exclusion criteria may apply
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07439796 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Healthy Volunteers - Male and Female. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07439796 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07439796 currently recruiting?
Yes, NCT07439796 is actively recruiting participants. Contact the research team at ClinicalTrials@ornatx.com for enrollment information.
Where is the NCT07439796 trial being conducted?
This trial is being conducted at Herston, Australia.
Who is sponsoring the NCT07439796 clinical trial?
NCT07439796 is sponsored by Orna Therapeutics, Inc.. The trial plans to enroll 20 participants.